Imaging PD-L1 in Tumors Using a Radioactive Probe in Solid Cancers
Tests a radioactive PD-L1 imaging probe to detect the protein in solid tumors.
Plain-language title generated from the registry record
Registry title: Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a confirmed solid tumor, such as lung, cervical, breast or stomach and bowel cancer or melanoma. A scan with a PD-L1 probe checks how much PD-L1 the tumor shows.
- Age
- Older than 18 years
- Sex
- All sexes can join
- Disease stage
- Pathologically confirmed solid tumor (lung cancer, cervical cancer, melanoma, breast cancer, gastrointestinal tumor, etc.), recent recurrence or suspected recurrence of a previous solid tumor. At least one measurable tumor lesion (RECIST1.1). ECOG score 0 or 1. Predicted survival of at least 12 weeks.
Main reasons for not taking part
- Severe abnormal liver or kidney function
- Pregnant, planning pregnancy or breastfeeding women
- Cannot lie flat for half an hour
- Claustrophobia or other mental illness
- Known allergy to the study drug or its excipients
Read by machine on 13 November 2026.
Where in China
- Beijing Cancer HospitalBeijing, ChinaContact: Hua ZhuTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Peking University Cancer Hospital & Institute
- Trial code
- NCT07848243
- Record updated
- 29 September 2026
- Original description
[18F]F-PDL1-3 molecular probe was used to detect the expression of PD-L1 in primary and metastatic tumors of patients with solid tumors. The heterogeneity of PD-L1 expression in the same lesion and different lesions was further evaluated, and the changes of PD-L1 expression in the course of the disease were observed. This method is helpful for the screening of patients with solid tumors with high PD-L1 expression, efficacy monitoring, and early warning of drug resistance and/or recurrence or metastasis, and ultimately achieve individualized targeted therapy of tumorsRead full original descriptionShow less
Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes
[18F]F-PDL1-3 molecular probe was used to detect the expression of PD-L1 in primary and metastatic tumors of patients with solid tumors. The heterogeneity of PD-L1 expression in the same lesion and different lesions was further evaluated, and the changes of PD-L1 expression in the course of the disease were observed. This method is helpful for the screening of patients with solid tumors with high PD-L1 expression, efficacy monitoring, and early warning of drug resistance and/or recurrence or metastasis, and ultimately achieve individualized targeted therapy of tumors
Inclusion: Age >18 years old, ECOG score 0 or 1; subjects with pathologically confirmed solid tumors (lung cancer, cervical cancer, melanoma, breast cancer, gastrointestinal tumor, etc.), recent recurrence or suspected recurrence of previous solid tumors; There was at least one measurable target lesion according to RECIST1.1 criteria; Predicted survival time ≥12 weeks; Blood routine, liver and kidney function meet the following standards: see the study protocol for specific requirements; Women must be using an effective contraceptive method (effective contraception means sterilization, intrauterine hormonal devices, condoms, contraceptives/pills, abstinence, or partner's removal of the vas deferentia) during the study and for 6 months after the study; Men should consent to subjects who must use contraception during the study period and for 6 months after the end of the study period; Subjects can fully understand and voluntarily participate in this experiment, and sign an informed consent. Compliance was good.
Exclusion: Known allergy to the investigational drug or its excipients in the study treatment; Other circumstances considered by the investigator to be inappropriate for trial participation; Claustrophobia or other mental illness; Severe abnormal liver and kidney function; Pre-pregnancy, pregnant and lactating women; Unable to lie flat for half an hour; Refusal to be a clinical investigator.